Eli Lilly and Company $LLY Stock Position Lessened by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 13.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,012 shares of the company’s stock after selling 904 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $4,687,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of LLY. WestEnd Advisors LLC grew its stake in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter worth $27,000. Blume Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares in the last quarter. Citizens National Bank Trust Department grew its stake in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Finally, IMG Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth $35,000. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on LLY. BMO Capital Markets upped their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a report on Monday. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. UBS Group cut their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Trading Up 1.6%

Shares of NYSE LLY opened at $812.33 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The company has a market cap of $768.84 billion, a price-to-earnings ratio of 53.09, a P/E/G ratio of 1.14 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a fifty day simple moving average of $762.81 and a 200-day simple moving average of $766.75.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last 90 days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.